Related Experiment Video
Updated: Jun 26, 2025
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal
An Ta1, Felicitas Kühne2, Maren Laurenz2
1Cytel, London, United Kingdom.
Insights
The 20-valent pneumococcal conjugate vaccine (PCV20) offers superior clinical and economic benefits compared to PCV13 and PCV15 in Germany. Implementing PCV20 is projected to significantly reduce pneumococcal disease cases and healthcare costs.
Area of Science:
- Vaccinology
- Public Health
- Health Economics
Background:
- Germany utilizes the 13-valent pneumococcal conjugate vaccine (PCV13) for infants, achieving substantial reductions in pneumococcal disease (PD).
- Higher-valent vaccines present an opportunity to further decrease the PD burden.
Purpose of the Study:
- To conduct a cost-effectiveness analysis comparing the 20-valent pneumococcal conjugate vaccine (PCV20) with 15-valent (PCV15) and 13-valent (PCV13) vaccines in Germany's pediatric population.
- To evaluate the clinical and economic impact of PCV20 using a 3+1 schedule versus PCV15 and PCV13 using a 2+1 schedule.
Main Methods:
- A 10-year Markov model simulated the impact of pediatric vaccination strategies.
- Data on clinical effectiveness, epidemiology, utility, and medical costs were sourced from existing studies.
- The analysis adopted a German societal perspective, discounting benefits and costs at 3%.
Main Results:
- PCV20 dominated PCV13, averting over 15,000 invasive PD cases, more than 930,000 pneumonia cases, over 530,000 otitis media cases, and nearly 60,000 deaths, while saving over €2.39 billion.
- PCV20 also dominated PCV15, preventing additional cases of IPD, pneumonia, and otitis media, alongside saving lives.
- Sensitivity analyses confirmed the robustness of these findings.
Conclusions:
- The 20-valent pneumococcal conjugate vaccine (PCV20) administered on a 3+1 schedule demonstrates dominance over both PCV13 and PCV15 on a 2+1 schedule over a 10-year period.
- Wider serotype coverage of PCV20 translates to significant clinical and economic advantages.
- Replacing lower-valent vaccines with PCV20 is recommended for enhanced public health and economic outcomes in Germany.
Introduction:
Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany's Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany's pediatric population.
Methods:
A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs).
Results:
In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses.
Conclusion:
PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20's broader serotype coverage.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Preventive Healthcare Services
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations
01:30Pneumonia III: Complications and Assessment